Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT06462365 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) |
| recruiting |
| Phase 1 |
| 36 |
| Tr1X, Inc.INDUSTRY |
| 1 |
| Apr 15, 2025 |
| clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06245746 | UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia | recruiting | Phase 1 | 9 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05947344 | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05662904 | Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML(GALAXY33) | not yet recruiting | Phase 1 | 12 | German Cancer Research CenterOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05190471 | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 48 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06613217 | Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia | recruiting | Phase 1 | 35 | Pacylex PharmaceuticalsINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06835140 | CD123-CD16-NK Cells Immunotherapy for AML(CD123-CD16-NK) | recruiting | Phase 1 | 9 | Chunji GaoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06651866 | Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06737523 | Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML | recruiting | Phase 1 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06731699 | A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS | recruiting | Phase 1 | 72 | Chengdu FenDi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT06034275 | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies | recruiting | Phase 1 | 36 | Vincerx Pharma, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06420063 | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML(BAH244) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | active not recruiting | Phase 1 | 88 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05503134 | Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML(KARMA) | recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | recruiting | Phase 1 | 102 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06550713 | A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies | recruiting | Phase 1 | 100 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06463327 | ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML(ACHIEVE2) | not yet recruiting | Phase 1 | 69 | TC BiopharmINDUSTRY | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06441084 | A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation | not yet recruiting | Phase 1 | 15 | Nuwacell Biotechnologies Co., Ltd.INDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 180 | AkesoINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05319249 | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia(NAKIP-AML) | not yet recruiting | Phase 1 / Phase 2 | 54 | German Cancer Research CenterOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06347458 | BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children | not yet recruiting | Phase 1 | 24 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT04243785 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 80 | Edgewood Oncology Inc.INDUSTRY | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06252584 | Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients(AML-VAC-XS15) | not yet recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 0 | Feb 9, 2024 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT04167696 | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02(CYCLE-1) | recruiting | Phase 1 | 27 | Celyad Oncology SAINDUSTRY | 2 | Jun 9, 2020 | clinicaltrials |
Data updated 22 days agoSource updated May 11, 2025source: clinicaltrials